Your browser is no longer supported. Please, upgrade your browser.
Settings
SLNO Soleno Therapeutics, Inc. daily Stock Chart
SLNO [NASD]
Soleno Therapeutics, Inc.
Index- P/E- EPS (ttm)-0.62 Insider Own17.50% Shs Outstand32.70M Perf Week-2.46%
Market Cap90.91M Forward P/E- EPS next Y-0.83 Insider Trans- Shs Float26.22M Perf Month1.09%
Income-15.60M PEG- EPS next Q-0.18 Inst Own57.90% Short Float0.56% Perf Quarter37.62%
Sales- P/S- EPS this Y-329.90% Inst Trans-0.21% Short Ratio1.75 Perf Half Y58.86%
Book/sh0.74 P/B3.76 EPS next Y-20.60% ROA- Target Price12.00 Perf Year0.72%
Cash/sh0.62 P/C4.50 EPS next 5Y- ROE- 52W Range1.11 - 5.07 Perf YTD62.57%
Dividend- P/FCF- EPS past 5Y26.70% ROI- 52W High-46.15% Beta2.26
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin- 52W Low145.95% ATR0.21
Employees12 Current Ratio9.30 Sales Q/Q- Oper. Margin- RSI (14)51.17 Volatility6.65% 7.77%
OptionableNo Debt/Eq0.00 EPS Q/Q-31.40% Profit Margin- Rel Volume0.59 Prev Close2.78
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume84.54K Price2.73
Recom2.00 SMA20-1.39% SMA505.71% SMA20032.26% Volume23,536 Change-1.80%
Feb-13-18Reiterated Maxim Group Buy $8 → $4
Jul-15-19 09:00AM  Capnia, Inc. (SLNO) Upgraded to Strong Buy: Here's What You Should Know Zacks
Jul-11-19 11:14AM  FDA Accepts Neurocrine's NDA for Parkinson's Disease Drug Zacks
Jul-01-19 08:39AM  La Jolla (LJPC) Secures Positive CHMP Opinion for Giapreza Zacks
Jun-12-19 08:00AM  Soleno Therapeutics Announces Appointment of Veteran Industry Executive Birgitte Volck, M.D., Ph.D., to Board of Directors GlobeNewswire
May-28-19 06:07AM  Will Capnia to Surge Higher? Zacks +6.28%
May-24-19 08:49AM  What Kind Of Shareholders Own Soleno Therapeutics, Inc. (NASDAQ:SLNO)? Simply Wall St.
May-13-19 08:00AM  Soleno Therapeutics Provides Corporate Update and Reports First Quarter 2019 Financial Results GlobeNewswire
May-06-19 04:13PM  Soleno Therapeutics (SLNO) to Post Q1 Earnings: What's Up? Zacks
08:11AM  Small Drug Stocks Outlook: Near-Term Prospects Encouraging Zacks
Apr-29-19 08:00AM  Soleno Therapeutics Announces Appointment of Industry Veteran Gwen A. Melincoff to Board of Directors GlobeNewswire
Apr-03-19 08:00AM  Soleno Therapeutics to Present at the 2019 H.C. Wainwright Global Life Sciences Conference GlobeNewswire +5.56%
Mar-27-19 08:46AM  Will Capnia Continue to Surge Higher? Zacks -6.42%
Mar-25-19 10:00AM  Are You Looking for a Top Momentum Pick? Why Capnia, Inc. (SLNO) is a Great Choice Zacks
08:00AM  Soleno Therapeutics to Participate in the ROTH Battle of NASH Thrones Spring Investor Conference GlobeNewswire
Mar-20-19 07:48AM  Soleno Therapeutics Inc (SLNO) Files 10-K for the Fiscal Year Ended on December 31, 2018 GuruFocus.com -10.09%
Mar-18-19 08:30AM  Soleno Therapeutics, Analyst Review and Pipeline Progress ACCESSWIRE
08:00AM  Soleno Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2018 Financial Results GlobeNewswire
Mar-15-19 04:05PM  Four Healthcare Stocks Picking Up Speed On Friday ACCESSWIRE +98.52%
03:00PM  Soleno Therapeutics News: Why SLNO Stock Is Skyrocketing Today InvestorPlace
07:39AM  The Daily Biotech Pulse: KaryoPharm's Selinexor Review Delayed, FDA Accepts Adamis Opioid Overdose Drug NDA Benzinga
Mar-14-19 05:32PM  Soleno Therapeutics Announces Positive Outcome from Planned Data Safety Monitoring Board Review of Phase III DESTINY PWS Clinical Trial of DCCR in Prader-Willi Syndrome Business Wire
Mar-11-19 04:05PM  Soleno Therapeutics to Participate in Two Upcoming Investor Conferences GlobeNewswire
Dec-19-18 04:01PM  Soleno Therapeutics Announces $16.5 Million Private Placement GlobeNewswire
Dec-12-18 06:47AM  Is Soleno Therapeutics, Inc.s (NASDAQ:SLNO) CEO Pay Justified? Simply Wall St. -8.14%
Nov-15-18 08:05AM  Soleno Therapeutics Presents Clinical Fat Loss Data on DCCR at the Obesity Society Meeting 2018 GlobeNewswire
08:00AM  Soleno Therapeutics Provides Corporate Update and Reports Third Quarter 2018 Financial Results GlobeNewswire
Oct-08-18 08:00AM  Soleno Therapeutics Presents Clinical Data on DCCR at 2018 Foundation for Prader-Willi Research Annual Conference GlobeNewswire -11.31%
Oct-01-18 08:00AM  Soleno Therapeutics Presents Clinical Data on DCCR at Late-Breaking Session of European Society for Paediatric Endocrinology GlobeNewswire +5.09%
Sep-19-18 08:00AM  Soleno Therapeutics to Participate in Oppenheimer Fall Summit Focused on Specialty Pharma and Rare Disease GlobeNewswire
Sep-17-18 08:00AM  Soleno Therapeutics to Present DCCR Clinical Data at Late Breaking Sessions of the European Society for Paediatric Endocrinology GlobeNewswire
Sep-06-18 08:00AM  Soleno Therapeutics Announces Expansion of Ongoing Phase III Trial of DCCR in Prader-Willi Syndrome to Include Younger Patients GlobeNewswire
Sep-04-18 08:00AM  Soleno Therapeutics Announces Issuance of New U.S. Patent for DCCR Covering Treatment of Low Lean Body Mass in Prader-Willi Syndrome GlobeNewswire
Aug-14-18 04:05PM  Soleno Therapeutics Provides Corporate Update and Reports Second Quarter 2018 Financial Results GlobeNewswire
Jul-30-18 08:00AM  Soleno Therapeutics Receives Fast Track Designation from FDA for DCCR for Treatment of Prader-Willi Syndrome GlobeNewswire +8.66%
Jun-04-18 08:00AM  Soleno Therapeutics To Present Corporate Update at the BIO International Convention GlobeNewswire
May-16-18 08:00AM  Soleno Therapeutics Provides Corporate Update and Reports First Quarter 2018 Financial Results GlobeNewswire
May-14-18 08:00AM  Soleno Therapeutics Announces Initiation of Phase III Clinical Trial of DCCR in Prader-Willi Syndrome GlobeNewswire +20.25%
Apr-03-18 06:15PM  What Should You Know About Soleno Therapeutics Incs (NASDAQ:SLNO) Future? Simply Wall St.
Apr-02-18 08:00AM  Soleno Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2017 Financial Results GlobeNewswire
Mar-26-18 08:48PM  Does Soleno Therapeutics Incs (NASDAQ:SLNO) Past Performance Indicate A Weaker Future? Simply Wall St.
Mar-16-18 06:14PM  Soleno Therapeutics Inc (NASDAQ:SLNO): Is Breakeven Near? Simply Wall St.
Feb-20-18 08:00AM  Soleno Therapeutics Announces Successful End-of-Phase II Meeting with FDA for DCCR in Prader-Willi Syndrome GlobeNewswire
Dec-12-17 08:30AM  Soleno Therapeutics Announces $15 Million Private Placement GlobeNewswire
Dec-11-17 08:10AM  Todays Research Reports on Stocks to Watch: Soleno Therapeutics and La Jolla Pharmaceutical Company ACCESSWIRE
Dec-08-17 05:43PM  Is Soleno Therapeutics Incs (SLNO) Balance Sheet Strong Enough To Weather A Storm? Simply Wall St. +10.97%
08:00AM  Soleno Therapeutics Announces Joint Venture Agreement for Development and Commercialization of CoSense Monitoring Technology GlobeNewswire
Nov-30-17 03:15PM  Should Soleno Therapeutics Incs (SLNO) Earnings Decline In Recent Times Worry You? Simply Wall St.
Nov-22-17 08:00AM  Soleno Therapeutics to Present at the Piper Jaffray 29th Annual Healthcare Conference GlobeNewswire
Nov-14-17 03:59PM  What Is Soleno Therapeutics Incs (SLNO) Share Price Doing? Simply Wall St. -12.08%
08:00AM  Soleno Therapeutics Provides Corporate Update and Reports Third Quarter 2017 Financial Results GlobeNewswire
Oct-23-17 08:00AM  Soleno Therapeutics Regains Compliance with NASDAQ Listing Requirements GlobeNewswire
Oct-12-17 08:00AM  Soleno Therapeutics Receives Positive Opinion from European Orphan Committee for DCCR in Prader-Willi Syndrome GlobeNewswire
Oct-11-17 08:00AM  Soleno Therapeutics Announces Issuance of New U.S. Patent for DCCR Covering Treatment of Hyperphagia in Prader-Willi Syndrome GlobeNewswire +7.98%
Oct-05-17 01:00PM  Soleno Therapeutics Announces 1-for-5 Reverse Stock Split GlobeNewswire -8.46%
Sep-25-17 08:00AM  Soleno Therapeutics Announces Receipt of Scientific Advice from the European Medicines Agency for DCCR in Prader-Willi Syndrome GlobeNewswire
Sep-12-17 03:37PM  Before You Buy Soleno Therapeutics Incs (SLNO), You Should Consider This Simply Wall St.
Aug-24-17 11:22AM  Soleno Therapeutics, Inc. :SLNO-US: Earnings Analysis: Q2, 2017 By the Numbers : August 24, 2017 Capital Cube +12.86%
Soleno Therapeutics, Inc. focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is diazoxide choline controlled-release, a tablet that is in Phase III clinical trial for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.